Alert

Fresenius Medical Care AG (FMS)

NYSE: FMS · Real-Time Price · USD

23.43

-0.41 (-1.72%)

At close: Aug 20, 2026, 3:59 PM

23.51

+0.38%

Pre-market: 8:30 AM

The price, the headline numbers and the latest news, in one place.

-1.72% (1D)

Bid	23.01
Market Cap	12.47B
Revenue (ttm)	19.43B
Net Income (ttm)	937.78M
	0.84
	1.92
	12.2
	6.44
P/B (ttm)	0.86
P/S (ttm)	0.64
Earnings Date	Nov 3, 2026

Ask	24.13
Volume	787,068
Avg. Volume (20D)	729,067
Open	23.68
Previous Close	23.84
Day's Range	23.30 - 23.91
52-Week Range	20.02 - 27.64
Analyst	Hold
Price Target	25.41 (8.45%)
Dividends	$0.87 (3.72%)
Ex-Dividend Date	May 22, 2026

About FMS

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient'...

[Read more]

Industry Medical Care Facilities

Sector Healthcare

IPO Date Sep 17, 1996

Employees 107,226

Stock Exchange NYSE

Ticker Symbol FMS

Website https://www.freseniusmedicalcare.com

Full Company Profile

Financial Performance

In 2025, Fresenius Medical Care's revenue was 19.63B, an increase of 1.51% compared to the previous year's 19.34B. Earnings were 978.37M, an increase of 81.88%.

Financial Statements

Analyst Forecast

According to 7 analyst ratings, the average rating for FMS stock is "Hold". The 12-month stock price forecast is 25.41, which is upside of 8.45% from the latest price.

Stock Forecasts

Earnings Surprise

Fresenius Medical Care has released their quarterly earnings on Aug 3, 2026:

Revenue of n/a misses estimates by $0, with -100.00% YoY decline.

EPS of 0.56 exceeds estimates by 0.06, with 21.74% YoY growth.

Next Earnings Release

Fresenius Medical Care AG is scheduled to release its earnings on Nov 3, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 week ago · Motley Fool

Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript

U.S. referral execution gap offset by strong margin expansion and transformation savings.

2 weeks ago · Zacks

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

2 weeks ago · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Expands BEACON US To Build Its Case For HVHDF

Fresenius Medical Care is expanding its BEACON-US clinical initiative to build real-world evidence for high-volume hemodiafiltration therapy in the U.S. The program evaluates the 5008X CAREsystem and ...

2 weeks ago · Simply Wall St.

Fresenius Medical Care (XTRA:FME) Stock Looks Like A Bargain Despite Weak Returns

Fresenius Medical Care stock has recovered modestly in the short term yet is still down about 30% over the past five years, while recent valuation checks suggest the market may be pricing it on the ch...

2 weeks ago · Simply Wall St.

Is Fresenius Medical Care (XTRA:FME) Undervalued Following Its New CEO Appointment?

Fresenius Medical Care (XTRA:FME) has drawn fresh attention after the Supervisory Board appointed Cassie McLean as Management Board member and Chief Executive Officer of the Care Delivery segment, res...

Page 1 of 2

Fresenius Medical Care AG (FMS)